Review Papers Claim by Claim

• Fetus (in utero): High GLUT1, HK‑I, fetal PFK and PK isoforms; high glycogen; placenta/lactate supply; low long‑chain fatty acids and limited CPT1/carnitine availability — favors glycolysis and lactate oxidation.
  Fetal glycolytic program (Ascuitto 1996)
• Perinatal transition: Birth → rise in arterial PO2, increase in circulating free fatty acids (milk), thyroid/hormonal signals, isoform switches (GLUT1→GLUT4; M↔H LDH; HK isoforms), mitochondrial biogenesis (increased cristae, respiratory enzymes) and PDH regulatory changes — enabling oxidative FAO rise.
  Perinatal mitochondrial maturation (Ascuitto 1996)
• Neonate (early days): Rapid upregulation of FA oxidation capacity (species- and age-dependent: pig/rabbit show rapid increases over first ~7–14 days), but retained high glycolytic reserve that confers resilience to hypoxia/low-flow ischemia.
  Postnatal FAO rise and glycolytic reserve (Ascuitto 1996)

• Comprehensive synthesis across multiple species and experimental platforms (in vivo fetal lamb, isolated perfused pig/rabbit hearts, NMR) providing convergent evidence for a perinatal metabolic program (Review scope and methods (Ascuitto 1996)).
• Mechanistic layering: enzyme isoform shifts, PDH regulation, carnitine/CPT control, and substrate competition (Randle-like interactions) suitably explain observed flux changes.
• Clinically relevant interpretation: ties between neonatal substrate state and tolerance to hypoxia/ischemia are clearly presented and translationally useful for neonatal cardiac care.

• Species differences: much evidence is from lamb, pig, rabbit — extrapolation to human neonates is plausible but not proven; review acknowledges interspecies variability and sampling-method differences (Species caveats (Ascuitto 1996)).
• Older methods: many referenced experiments predate high-resolution omics and modern metabolic flux technologies — isotopomer 13C-NMR and Seahorse-based slice assays improve flux resolution today; their absence limits mechanistic specificity in some claims (13C isotopomer flux methods (1990)).
• Missing neonatal ketone biology: modern work shows neonatal ketone elevation (HMGCS2-driven) is a key perinatal signal for mitochondrial maturation and FA oxidation competence (not available to 1996 authors). This is a conceptual blindspot the review could not address (Neonatal ketone signaling (Hmgcs2, 2022)).
• Heterogeneous quantitation: some numeric statements in the review derive from varied preparations (recirculating perfusate, nonrecirculating Langendorff, in vivo AV differences) — this complicates direct aggregation of rates across studies.

1. Neonatal cardiac support: glucose availability and insulin responsiveness matter in the early newborn; exogenous glucose ± insulin can delay ischemic contracture in experimental hearts, suggesting metabolic substrate management during neonatal cardiac stress is critical (Glucose support during neonatal ischemia (Ascuitto 1996)).
2. Therapeutic modulation: modern strategies (e.g., PDH activation with DCA) were noted in the review; subsequent work must be read cautiously because species and developmental stage change efficacy (DCA and PDH modulation (Ascuitto 1996)).
3. Research design: modern studies should pair high-resolution flux methods (13C isotopomer NMR, Seahorse fuel-flex on organotypic slices) with genetic models (Hmgcs2, CPT1 manipulations) and perinatal nutritional/hormonal perturbations — this will close gaps noted by the review (Seahorse slice method (2025)).

• Novelty: The review synthesized then-recent cross-species data and framed perinatal metabolic transitions — novel in 1996 because it pulled diverse methodologies into a cohesive model; key modern additions (ketone signaling, omics) post-date it.
• Quality: High-quality scholarship for its time (extensive referencing, balanced presentation), with transparent methodological caveats; lacks later tools/data (omics, genetic KOs) that now refine mechanisms.

The review’s broad conclusions (glycolysis→FAO shift; neonatal glycolytic reserve) would be substantially strengthened, mechanistically updated, or nuanced by:

• Quantitative 13C-isotopomer flux maps across perinatal days in human-relevant models (human iPSC‑CMs matured in FA media, neonatal pig in vivo) to assign absolute fluxes to PDH, β‑oxidation and anaplerosis (13C isotopomer methodology (1990)).
• Genetic manipulation (Hmgcs2, CPT1b, Pdk4) to test causal roles of neonatal ketone production, carnitine/CPT1 regulation and PDH control in perinatal mitochondrial maturation and ischemic resilience (Hmgcs2 KO evidence (2022)).
• Human neonatal clinical measurements (noninvasive NMR, biomarkers of ketones/carnitine/PDH activity) to validate translatability.